Aptose Biosci 
Welcome,         Profile    Billing    Logout  
 3 Products   9 Diseases  3 Products   3 Trials   254 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luxeptinib (CG-806) / Aptose Biosci
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Terminated
1
36
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
05/24
05/24
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Terminated
1
45
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/24
04/24
tuspetinib (HM43239) / Aptose Biosci
TUSCANY, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
luxeptinib (CG-806) / Aptose Biosci
NCT03893682: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Terminated
1
36
US
CG-806, Luxeptinib
Aptose Biosciences Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
05/24
05/24
NCT04477291: A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

Terminated
1
45
US
CG-806
Aptose Biosciences Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
04/24
04/24
tuspetinib (HM43239) / Aptose Biosci
TUSCANY, NCT03850574: Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
240
Europe, US, RoW
Tuspetinib, HM43239, Venetoclax Oral Tablet, Venetoclax, Azacitidine for Intravenous Infusion, Azacitidine
Aptose Biosciences Inc.
Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML, Myelodysplastic Syndrome with Excess Blasts-2, Chronic Myelomonocytic Leukemia
11/26
04/27

Download Options